BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531-3540. [PMID: 20547994 DOI: 10.1200/jco.2009.27.4787] [Cited by in Crossref: 139] [Cited by in F6Publishing: 87] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Nie J, Zhang J, Wang L, Lu L, Yuan Q, An F, Zhang S, Jiao Y. Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4. J Exp Clin Cancer Res 2017;36:183. [PMID: 29237483 DOI: 10.1186/s13046-017-0641-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kim ST, Jang KT, Lee J, Jang HM, Choi HJ, Jang HL, Park SH, Park YS, Lim HY, Kang WK, Park JO. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol 2015;8:40-6. [PMID: 25749176 DOI: 10.1016/j.tranon.2014.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
3 Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, Itoh K, Sasada T. Current status of immunotherapy for the treatment of biliary tract cancer. Hum Vaccin Immunother. 2013;9:1069-1072. [PMID: 23376808 DOI: 10.4161/hv.23844] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
4 Goeppert B, Frauenschuh L, Zucknick M, Roessler S, Mehrabi A, Hafezi M, Stenzinger A, Warth A, Pathil A, Renner M, Schirmacher P, Weichert W. Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br J Cancer 2015;113:1343-9. [PMID: 26461054 DOI: 10.1038/bjc.2015.337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
5 Saha SK, Parachoniak CA, Bardeesy N. IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle 2014;13:3176-82. [PMID: 25485496 DOI: 10.4161/15384101.2014.965054] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
6 Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819-828. [PMID: 24852116 DOI: 10.1016/s1470-2045(14)70212-8] [Cited by in Crossref: 220] [Cited by in F6Publishing: 120] [Article Influence: 31.4] [Reference Citation Analysis]
7 Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 2014;5:2839-52. [PMID: 24867389 DOI: 10.18632/oncotarget.1943] [Cited by in Crossref: 101] [Cited by in F6Publishing: 153] [Article Influence: 16.8] [Reference Citation Analysis]
8 Chung SY, Hung YP, Pan YR, Chang YC, Wu CE, Hsu DS, Chang PM, Lu ML, Huang CF, Su Y, Hsiao M, Yeh CN, Chen MH. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines 2021;9:885. [PMID: 34440089 DOI: 10.3390/biomedicines9080885] [Reference Citation Analysis]
9 Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021;148:702-712. [PMID: 32700810 DOI: 10.1002/ijc.33230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
10 Sakamoto S, Yoshitomi M, Yutani S, Terazaki Y, Yoshiyama K, Ioji T, Matsueda S, Yamada A, Takamori S, Itoh K, Hattori N, Kohno N, Sasada T. Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination. Hum Vaccin Immunother 2015;11:2784-9. [PMID: 26325075 DOI: 10.1080/21645515.2015.1075107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Wu CE, Chou WC, Hsieh CH, Chang JW, Lin CY, Yeh CN, Chen JS. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience. BMC Cancer 2020;20:422. [PMID: 32410631 DOI: 10.1186/s12885-020-06914-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020;73:315-27. [PMID: 32173382 DOI: 10.1016/j.jhep.2020.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 29.0] [Reference Citation Analysis]
13 Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol 2016; 22(4): 1335-1347 [PMID: 26819503 DOI: 10.3748/wjg.v22.i4.1335] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
14 Laface C, Laforgia M, Molinari P, Ugenti I, Gadaleta CD, Porta C, Ranieri G. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers (Basel) 2021;13:3091. [PMID: 34205656 DOI: 10.3390/cancers13123091] [Reference Citation Analysis]
15 Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, Gumus Y, Chebib A, Almohamad W, Innominato PF. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 2020;20:515. [PMID: 32493242 DOI: 10.1186/s12885-020-07004-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Huang L, Chen W, Liang P, Hu W, Zhang K, Shen S, Chen J, Zhang Z, Chen B, Han Y, Meng F, DeMorrow S, Yin X, Lai J, Liang L. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma. Dig Dis Sci. 2015;60:1273-1283. [PMID: 25487191 DOI: 10.1007/s10620-014-3472-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
17 Oyasiji T, Zhang J, Kuvshinoff B, Iyer R, Hochwald SN. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. Oncologist 2015;20:742-51. [PMID: 26025932 DOI: 10.1634/theoncologist.2014-0442] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
18 Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. Br J Cancer 2014;111:430-6. [PMID: 24960403 DOI: 10.1038/bjc.2014.343] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
19 Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014;20:1884-1890. [PMID: 24478380 DOI: 10.1158/1078-0432.ccr-13-2649] [Cited by in Crossref: 75] [Cited by in F6Publishing: 42] [Article Influence: 10.7] [Reference Citation Analysis]
20 Maharaj R, Cave C, Sarran K, Bascombe N, Dan D, Greaves W, Warner WA. A case report of the clear cell variant of gallbladder carcinoma. Int J Surg Case Rep 2017;32:36-9. [PMID: 28222323 DOI: 10.1016/j.ijscr.2017.01.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Kim ST, Jang KT, Lee SJ, Jang HL, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer 2015;15:530. [PMID: 26189560 DOI: 10.1186/s12885-015-1552-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
22 Mikhitarian K, Pollen M, Zhao Z, Shyr Y, Merchant NB, Parikh A, Revetta F, Washington MK, Vnencak-Jones C, Shi C. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. Mod Pathol. 2014;27:665-674. [PMID: 24186143 DOI: 10.1038/modpathol.2013.185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
23 Sasaki T, Isayama H, Nakai Y, Koike K. Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med. 2013;28:515-524. [PMID: 24009445 DOI: 10.3904/kjim.2013.28.5.515] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
24 Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Mol Oncol 2017;11:1130-42. [PMID: 28544747 DOI: 10.1002/1878-0261.12078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
25 He X, Zhu Y, Wang Y, Hao Y, Hong J. Advances in stent therapy for malignant biliary obstruction. Abdom Radiol (NY). 2021;46:351-361. [PMID: 32451676 DOI: 10.1007/s00261-020-02593-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Ostwal V, Swami R, Patkar S, Majumdar S, Goel M, Mehta S, Engineer R, Mandavkar S, Kumar S, Ramaswamy A. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward. Med Oncol 2018;35:57. [PMID: 29564657 DOI: 10.1007/s12032-018-1115-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-2179. [PMID: 24581682 DOI: 10.1016/s0140-6736(13)61903-0] [Cited by in Crossref: 783] [Cited by in F6Publishing: 471] [Article Influence: 111.9] [Reference Citation Analysis]
28 Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget 2015;6:23594-608. [PMID: 26090720 DOI: 10.18632/oncotarget.4335] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
29 Turgeon MK, Maithel SK. Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy. Chin Clin Oncol 2020;9:4. [PMID: 31500433 DOI: 10.21037/cco.2019.08.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Li H, Zhao T, Ji X, Liang S, Wang Z, Yang Y, Yin J, Wang R. Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer. Tumour Biol 2016;37:3535-42. [PMID: 26453118 DOI: 10.1007/s13277-015-4184-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
31 Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F, Joehrens K, Warth A, Renner M, Mehrabi A. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 2013;109:2665-2674. [PMID: 24136146 DOI: 10.1038/bjc.2013.610] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 13.1] [Reference Citation Analysis]
32 Wu CE, Huang CY, Chen CP, Pan YR, Chang JW, Chen JS, Yeh CN, Lunec J. WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. Cancers (Basel) 2021;13:3876. [PMID: 34359777 DOI: 10.3390/cancers13153876] [Reference Citation Analysis]
33 Tang H, Lu W, Li B, Li C, Xu Y, Dong J. Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. Oncotarget 2017;8:36857-68. [PMID: 28415734 DOI: 10.18632/oncotarget.16143] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
34 Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies. Hepatology 2021;73 Suppl 1:49-61. [PMID: 32394479 DOI: 10.1002/hep.31310] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 18.0] [Reference Citation Analysis]
35 Li Q, Zhang Q, Cheng X, Weng X, Chen M, Hu X, Huang J, Chen J. Next-Generation Sequencing Characterizes the Landscape of Somatic Mutations and Pathways in Metastatic Bile Tract Carcinoma. J Oncol 2020;2020:3275315. [PMID: 32952556 DOI: 10.1155/2020/3275315] [Reference Citation Analysis]
36 Hryciuk B, Pęksa R, Bieńkowski M, Szymanowski B, Radecka B, Winnik K, Żok J, Cichowska N, Iliszko M, Duchnowska R. Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer. Sci Rep 2020;10:1871. [PMID: 32024900 DOI: 10.1038/s41598-020-58777-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513:110-114. [PMID: 25043045 DOI: 10.1038/nature13441] [Cited by in Crossref: 243] [Cited by in F6Publishing: 274] [Article Influence: 34.7] [Reference Citation Analysis]
38 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
39 Wutka A, Palagani V, Barat S, Chen X, El Khatib M, Götze J, Belahmer H, Zender S, Bozko P, Malek NP, Plentz RR. Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis. PLoS One 2014;9:e95605. [PMID: 24748170 DOI: 10.1371/journal.pone.0095605] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
40 Kanthan R, Senger JL, Ahmed S, Kanthan SC. Gallbladder Cancer in the 21st Century. J Oncol. 2015;2015:967472. [PMID: 26421012 DOI: 10.1155/2015/967472] [Cited by in Crossref: 106] [Cited by in F6Publishing: 111] [Article Influence: 17.7] [Reference Citation Analysis]
41 Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH, Yeh CN. Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncol Lett. 2018;16:566-572. [PMID: 29963132 DOI: 10.3892/ol.2018.8690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Goldstein D, Lemech C, Valle J. New molecular and immunotherapeutic approaches in biliary cancer. ESMO Open 2017;2:e000152. [PMID: 28848675 DOI: 10.1136/esmoopen-2016-000152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
43 Wu CE, Pan YR, Yeh CN, Lunec J. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules 2020;10:E1474. [PMID: 33113997 DOI: 10.3390/biom10111474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Bi J, Ma H, Liu Y, Huang A, Xiao Y, Shu WJ, Du H, Zhang T. Upregulation of PAIP1 promotes the gallbladder tumorigenesis through regulating PLK1 level. Ann Transl Med 2021;9:991. [PMID: 34277791 DOI: 10.21037/atm-21-2417] [Reference Citation Analysis]
45 Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012;3:463-9. [PMID: 22969912 DOI: 10.3892/etm.2011.424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
46 El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One. 2013;8:e77433. [PMID: 24204826 DOI: 10.1371/journal.pone.0077433] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
47 Shah UA, Nandikolla AG, Rajdev L. Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol 2017;18:44. [PMID: 28660602 DOI: 10.1007/s11864-017-0486-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
48 Trachu N, Sirachainan E, Larbcharoensub N, Rattanadech W, Detarkom S, Monnamo N, Kamprerasart K, MunTham D, Sukasem C, Reungwetwattana T. Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population. Onco Targets Ther 2017;10:4955-68. [PMID: 29066915 DOI: 10.2147/OTT.S143982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Uhl B, Dietrich D, Branchi V, Semaan A, Schaefer P, Gevensleben H, Rostamzadeh B, Lingohr P, Schäfer N, Kalff JC, Kristiansen G, Matthaei H. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS One 2016;11:e0165769. [PMID: 27798672 DOI: 10.1371/journal.pone.0165769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
50 Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 2015;17:982-7. [PMID: 26607930 DOI: 10.1007/s12094-015-1436-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
51 Pan YR, Wu CE, Chen MH, Huang WK, Shih HJ, Lan KL, Yeh CN. Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. Vaccines (Basel) 2020;8:E703. [PMID: 33255375 DOI: 10.3390/vaccines8040703] [Reference Citation Analysis]
52 Noel MS, Hezel AF. New and emerging treatment options for biliary tract cancer. Onco Targets Ther 2013;6:1545-52. [PMID: 24204165 DOI: 10.2147/OTT.S32545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
53 Zhao X, Zhang C, Zhou H, Xiao B, Cheng Y, Wang J, Yao F, Duan C, Chen R, Liu Y, Feng C, Li H, Li J, Dai R. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. Oncotarget 2016;7:85492-501. [PMID: 27863431 DOI: 10.18632/oncotarget.13408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
54 Rahnemai-Azar AA, Pandey P, Kamel I, Pawlik TM. Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. Hepat Oncol 2016;3:223-39. [PMID: 30191045 DOI: 10.2217/hep-2016-0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
55 Wu CE, Chen MH, Yeh CN. mTOR Inhibitors in Advanced Biliary Tract Cancers. Int J Mol Sci 2019;20:E500. [PMID: 30682771 DOI: 10.3390/ijms20030500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
56 Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-680. [PMID: 26172134 DOI: 10.1111/hpb.12441] [Cited by in Crossref: 177] [Cited by in F6Publishing: 208] [Article Influence: 35.4] [Reference Citation Analysis]
57 Dwivedi AND, Jain S, Dixit R. Gall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases 2015; 3(3): 231-244 [PMID: 25789296 DOI: 10.12998/wjcc.v3.i3.231] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
58 Alshari OM, Dawaymeh TA, Tashtush NA, Aleshawi AJ, Al Manasra ARA, Obeidat KA. Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases. Onco Targets Ther 2019;12:5293-8. [PMID: 31308699 DOI: 10.2147/OTT.S197559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
59 Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget 2014;5:2372-89. [PMID: 24796583 DOI: 10.18632/oncotarget.1706] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
60 Yokoyama M, Ohnishi H, Ohtsuka K, Matsushima S, Ohkura Y, Furuse J, Watanabe T, Mori T, Sugiyama M. KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. Jpn Clin Med 2016;7:33-9. [PMID: 28008299 DOI: 10.4137/JCM.S40549] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
61 Liu Z, Sun R, Zhang X, Qiu B, Chen T, Li Z, Xu Y, Zhang Z. Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1. EBioMedicine 2019;45:181-91. [PMID: 31248836 DOI: 10.1016/j.ebiom.2019.06.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
62 Laoveeravat P, Jaruvongvanich V, Wongjarupong N, Linlawan S, Tanpowpong N, Phathong C, Phatharacharukul P, Treeprasertsuk S, Rerknimitr R, Chaiteerakij R. Outcome and validation of a new clinically based staging system for predicting survival of perihilar cholangiocarcinoma patients. JGH Open 2017;1:56-61. [PMID: 30483535 DOI: 10.1002/jgh3.12009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Yoo KH, Kim NK, Kwon WI, Lee C, Kim SY, Jang J, Ahn J, Kang M, Jang H, Kim ST, Ahn S, Jang KT, Park YS, Park WY, Lee J, Heo JS, Park JO. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Transl Oncol 2016;9:173-8. [PMID: 27267833 DOI: 10.1016/j.tranon.2016.01.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
64 Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32:4861-4870. [PMID: 23318457 DOI: 10.1038/onc.2012.617] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 17.5] [Reference Citation Analysis]
65 Zimmer V, Höblinger A, Mihalache F, Assmann G, Acalovschi M, Lammert F. Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility. Oncol Lett 2012;4:101-6. [PMID: 22807971 DOI: 10.3892/ol.2012.680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
66 Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011;11:60. [PMID: 21303542 DOI: 10.1186/1471-2407-11-60] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
67 Lu Q, Fang T. Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma. J Clin Lab Anal 2020;34:e23138. [PMID: 31880360 DOI: 10.1002/jcla.23138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
68 Romiti A, D’Antonio C, Zullo A, Sarcina I, Di Rocco R, Barucca V, Durante V, Marchetti P. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer. 2012;43:396-404. [PMID: 22328060 DOI: 10.1007/s12029-012-9369-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
69 Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091-3100. [PMID: 22824796 DOI: 10.1038/onc.2012.315] [Cited by in Crossref: 224] [Cited by in F6Publishing: 274] [Article Influence: 24.9] [Reference Citation Analysis]
70 Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol 2016;7:819-27. [PMID: 28078106 DOI: 10.21037/jgo.2016.11.11] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
71 Ding N, Che L, Li XL, Liu Y, Jiang LJ, Fan B, Tao JY, Chen X, Ji JF. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World J Gastroenterol 2016; 22(6): 2071-2080 [PMID: 26877611 DOI: 10.3748/wjg.v22.i6.2071] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
72 Saqub H, Proetsch-Gugerbauer H, Bezrookove V, Nosrati M, Vaquero EM, de Semir D, Ice RJ, McAllister S, Soroceanu L, Kashani-Sabet M, Osorio R, Dar AA. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Sci Rep 2020;10:18489. [PMID: 33116269 DOI: 10.1038/s41598-020-75578-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
73 Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech. 2013;6:281-292. [PMID: 23520144 DOI: 10.1242/dmm.010561] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
74 Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016;122:758-65. [PMID: 26695839 DOI: 10.1002/cncr.29824] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 12.7] [Reference Citation Analysis]
75 Mondaca S, Nervi B, Pinto M, Abou-Alfa GK. Biliary tract cancer prognostic and predictive genomics. Chin Clin Oncol 2019;8:42. [PMID: 31431036 DOI: 10.21037/cco.2019.07.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
76 Carson SW, Craven KE, Nauen D, Montemayor K, Yarchoan M, Burns WR, Merlo CA, West NE. Rapidly progressive metastatic cholangiocarcinoma in a postpartum patient with cystic fibrosis: a case report. BMC Pulm Med 2020;20:298. [PMID: 33198722 DOI: 10.1186/s12890-020-01337-x] [Reference Citation Analysis]
77 Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829-40. [PMID: 23295441 DOI: 10.1053/j.gastro.2013.01.001] [Cited by in Crossref: 275] [Cited by in F6Publishing: 293] [Article Influence: 34.4] [Reference Citation Analysis]
78 Kato N, Yamamoto H, Adachi Y, Ohashi H, Taniguchi H, Suzuki H, Nakazawa M, Kaneto H, Sasaki S, Imai K, Shinomura Y. Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids. World J Gastroenterol 2013; 19(11): 1718-1727 [PMID: 23555160 DOI: 10.3748/wjg.v19.i11.1718] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
79 Kamp EJCA, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol 2021;14:17562848211002023. [PMID: 33948111 DOI: 10.1177/17562848211002023] [Reference Citation Analysis]
80 Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21:3827-3834. [PMID: 24889489 DOI: 10.1245/s10434-014-3828-x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 11.6] [Reference Citation Analysis]
81 Wu CE, Huang WK, Chou WC, Hsieh CH, Chang JW, Lin CY, Yeh CN, Chen JS. Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy. Cancers (Basel) 2021;13:3139. [PMID: 34201707 DOI: 10.3390/cancers13133139] [Reference Citation Analysis]
82 Tariq NU, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res 2019;11:2623-42. [PMID: 31015767 DOI: 10.2147/CMAR.S157092] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
83 Goeppert B, Truckenmueller F, Ori A, Fritz V, Albrecht T, Fraas A, Scherer D, Silos RG, Sticht C, Gretz N, Mehrabi A, Bewerunge-Hudler M, Pusch S, Bermejo JL, Dietrich P, Schirmacher P, Renner M, Roessler S. Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p. Sci Rep 2019;9:4796. [PMID: 30886199 DOI: 10.1038/s41598-019-40857-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
84 Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, Deshpande V. Microsatellite instability in gallbladder carcinoma. Virchows Arch 2015;466:393-402. [PMID: 25680569 DOI: 10.1007/s00428-015-1720-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
85 O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N, Hezel AF. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012;72:1557-1567. [PMID: 22266220 DOI: 10.1158/0008-5472.can-11-3596] [Cited by in Crossref: 109] [Cited by in F6Publishing: 71] [Article Influence: 12.1] [Reference Citation Analysis]
86 Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5:824-830. [PMID: 30998813 DOI: 10.1001/jamaoncol.2019.0270] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 105.0] [Reference Citation Analysis]
87 Ruys AT, van Beem BE, Engelbrecht MR, Bipat S, Stoker J, Van Gulik TM. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol. 2012;85:1255-1262. [PMID: 22919007 DOI: 10.1259/bjr/88405305] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 8.3] [Reference Citation Analysis]